Financial Information

Income Statement

v3.8.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]    
Net Sales $ 1,606,491 $ 167,899
Cost of Sales 355,453 88,173
Gross Profit 1,251,038 79,726
Operating expenses    
Compensation and related expenses 143,646 263,886
Professional fees 132,115 98,844
Marketing expenses 897,164 10,800
General and administrative expenses 357,427 107,989
Total operating expenses 1,530,352 481,519
Operating Loss (279,314) (401,793)
Change in fair value of derivative liability (48,192)
Interest (expense) (6,450) (649,357)
Loss from continuing operations (285,764) (1,099,342)
Income from discontinued operations, including gain on sale, net of income taxes 925,738 26,807
Net income (loss) 639,974 (1,072,535)
Net income (loss) attributable to noncontrolling interests 12,697 (27,730)
Net Income (loss) attributable to Immudyne, Inc. $ 627,277 $ (1,044,805)
Basic loss per share attributable to Immudyne, Inc. from continuing operation $ (0.01) $ (0.03)
Basic income per share attributable to Immudyne, Inc. from discontinued operation 0.02 0.00
Diluted loss per share attributable to Immudyne, Inc. from continuing operation (0.01) (0.03)
Diluted income per share attributable to Immudyne, Inc. from discontinued operation $ 0.02 $ 0.00
Average number of common shares outstanding    
Basic 43,509,730 37,581,987
Diluted 46,239,430 43,414,823

Source